Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 3 - 18 |
| Updated: | 3/7/2019 |
| Start Date: | October 2016 |
| End Date: | October 2020 |
RePPAIR -Reducing Procedural Pain and Improving Recovery of Quality of Life in Pediatric Neuroblastoma Patients Undergoing Bone Marrow Procedures: A Prospective Randomized Cross-over Clinical Trial
The purpose of this study is to identify whether or not the addition of a numbing medicine
that is injected directly into the site of the bone marrow procedure can reduce pain and the
use of opioid pain medication after bone marrow procedures. The addition of this medicine,
called ropivacaine, is the experimental part of this study. This is the first time
ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
that is injected directly into the site of the bone marrow procedure can reduce pain and the
use of opioid pain medication after bone marrow procedures. The addition of this medicine,
called ropivacaine, is the experimental part of this study. This is the first time
ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
Inclusion Criteria:
- Diagnosis of neuroblastoma as defined by the International Neuroblastoma Risk Group
Staging System (INRGSS)22
- 3 - 18 years of age
- Patient has had prior bone marrow procedures
- English speaking
Exclusion Criteria:
- History of allergy to investigational agent: ropivacaine or other amino amide
analgesics
- History of allergy to standard agent: propofol
- Chronic daily opioid requirement
- Lansky/Karnofsky Score < 60
- Inability to comply with protocol requirements including refusal to forego
pre-procedural opioid use
- Patient is receiving additional potentially painful interventions (e.g. central line
insertion/removal) concurrent with the bone marrow procedure
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Sara Zarnegar-Lumley, MD
Phone: 212-639-5966
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
